Angiotensin receptor-neprilysin inhibitors and cardiac remodeling

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling

The aim of this study was to determine how sacubitril/valsartan compared with valsartan in an outpatient setting affects left ventricular remodeling in heart failure with reduced ejection fraction and functional (or secondary) mitral regurgitation (SMR) due to the effect of dual inhibition of the re...

Full description

Bibliographic Details
Main Authors:	A.S. Ryazanov, E.V. Shikh, M.V. Makarovskaya, A.A. Kudryavtsev
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica 2023-04-01
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	Heart failure Cardiac remodeling Neprilysin Angiotensin receptor blockers
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2023000100625&tlng=en

Similar Items

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
by: A. S. Ryazanov, et al.
Published: (2023-01-01)

Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis
by: Yiwen Wang, et al.
Published: (2019-07-01)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
by: Su Yeong Park, et al.
Published: (2023-09-01)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
by: Hong-Mi Choi, et al.
Published: (2020-05-01)

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
by: Tomoko Kato, et al.
Published: (2023-09-01)

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
by: M. O.E. Irhuma, et al.
Published: (2016-11-01)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
by: Henry Sutanto, et al.
Published: (2021-08-01)

Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases
by: Hitoshi Nakagawa, et al.
Published: (2022-07-01)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
by: Kawa Dizaye, et al.
Published: (2019-05-01)

Anti-hypertensive effect of a novel angiotensin II receptor neprilysin inhibitor (ARNi) -S086 in DSS rat model
by: Jingchao Sun, et al.
Published: (2024-02-01)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
by: In-Jeong Cho, et al.
Published: (2021-12-01)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
by: Wipharak Rattanavipanon, et al.
Published: (2021-07-01)

Long‐term impact of angiotensin receptor‐neprilysin inhibitor based on short‐term treatment response in heart failure
by: Hyuk Kyoon Park, et al.
Published: (2023-12-01)

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
by: Toshio Nishikimi, et al.
Published: (2022-07-01)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
by: Sepideh Taghavi, et al.
Published: (2020-12-01)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
by: Kangbo Li, et al.
Published: (2023-02-01)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
by: Shao-Jung Hsu, et al.
Published: (2020-04-01)

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
by: Akihiro Nakamura, et al.
Published: (2023-01-01)

Angiotensin receptor‐neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime
by: Alessandra Arcudi, et al.
Published: (2022-10-01)

Initiation, treatment response evaluation, and safety monitoring of angiotensin receptor/neprilysin inhibitors (Sacubitril/Valsartan) in the management of heart failure in India: An expert group recommendations
by: Uday M Jadhav, et al.
Published: (2023-01-01)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
by: Yusuke Kashiwagi, et al.
Published: (2023-06-01)

Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
by: Donna S.‐H. Lin, et al.
Published: (2021-03-01)

Neprilysin Inhibitors and Bradykinin
by: Duncan J. Campbell, et al.
Published: (2018-09-01)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021-09-01)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Gregor Poglajen, et al.
Published: (2020-07-01)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study
by: Pankaj Jariwala, et al.
Published: (2021-01-01)

Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
by: Teng Y, et al.
Published: (2023-08-01)

The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19
by: Alessandro Bellis, et al.
Published: (2020-11-01)

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure
by: Amrita Mukhopadhyay, et al.
Published: (2022-12-01)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
by: Nathalie Esser, et al.
Published: (2022-06-01)

Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection
by: Shunichiro Tsukamoto, et al.
Published: (2023-04-01)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
by: Frederik H. Verbrugge, et al.
Published: (2020-07-01)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
by: Wanjing Li, et al.
Published: (2022-04-01)

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
by: Liangying Gan, et al.
Published: (2022-07-01)

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
by: Suriya Prausmüller, et al.
Published: (2020-06-01)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018-08-01)

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling
by: Kieran F. Docherty, et al.
Published: (2021-02-01)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
by: Pankaj Jariwala, et al.
Published: (2021-03-01)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
by: Brittany Chapman, et al.
Published: (2022-06-01)

Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data
by: Alvaro Alonso, et al.
Published: (2024-03-01)